227 related articles for article (PubMed ID: 38308278)
1. Natural carboxyterminal truncation of human CXCL10 attenuates glycosaminoglycan binding, CXCR3A signaling and lymphocyte chemotaxis, while retaining angiostatic activity.
Dillemans L; Yu K; De Zutter A; Noppen S; Gouwy M; Berghmans N; Verhallen L; De Bondt M; Vanbrabant L; Brusselmans S; Martens E; Schols D; Verschueren P; Rosenkilde MM; Marques PE; Struyf S; Proost P
Cell Commun Signal; 2024 Feb; 22(1):94. PubMed ID: 38308278
[TBL] [Abstract][Full Text] [Related]
2. Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling.
Metzemaekers M; Mortier A; Janssens R; Boff D; Vanbrabant L; Lamoen N; Van Damme J; Teixeira MM; De Meester I; Amaral FA; Proost P
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28703769
[TBL] [Abstract][Full Text] [Related]
3. A functional IFN-gamma-inducible protein-10/CXCL10-specific receptor expressed by epithelial and endothelial cells that is neither CXCR3 nor glycosaminoglycan.
Soejima K; Rollins BJ
J Immunol; 2001 Dec; 167(11):6576-82. PubMed ID: 11714827
[TBL] [Abstract][Full Text] [Related]
4. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10).
Campanella GS; Lee EM; Sun J; Luster AD
J Biol Chem; 2003 May; 278(19):17066-74. PubMed ID: 12571234
[TBL] [Abstract][Full Text] [Related]
5. Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity.
Hensbergen PJ; van der Raaij-Helmer EM; Dijkman R; van der Schors RC; Werner-Felmayer G; Boorsma DM; Scheper RJ; Willemze R; Tensen CP
Eur J Biochem; 2001 Sep; 268(18):4992-9. PubMed ID: 11559369
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.
Cox JH; Dean RA; Roberts CR; Overall CM
J Biol Chem; 2008 Jul; 283(28):19389-99. PubMed ID: 18411283
[TBL] [Abstract][Full Text] [Related]
7. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.
Proost P; Struyf S; Loos T; Gouwy M; Schutyser E; Conings R; Ronsse I; Parmentier M; Grillet B; Opdenakker G; Balzarini J; Van Damme J
Arthritis Res Ther; 2006; 8(4):R107. PubMed ID: 16846531
[TBL] [Abstract][Full Text] [Related]
8. The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan.
Yang J; Richmond A
Mol Ther; 2004 Jun; 9(6):846-55. PubMed ID: 15194051
[TBL] [Abstract][Full Text] [Related]
9. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3.
Campanella GS; Colvin RA; Luster AD
PLoS One; 2010 Sep; 5(9):e12700. PubMed ID: 20856926
[TBL] [Abstract][Full Text] [Related]
10. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
[TBL] [Abstract][Full Text] [Related]
11. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes.
Janssens R; Mortier A; Boff D; Ruytinx P; Gouwy M; Vantilt B; Larsen O; Daugvilaite V; Rosenkilde MM; Parmentier M; Noppen S; Liekens S; Van Damme J; Struyf S; Teixeira MM; Amaral FA; Proost P
Biochem Pharmacol; 2017 May; 132():92-101. PubMed ID: 28322746
[TBL] [Abstract][Full Text] [Related]
12. CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.
Van Raemdonck K; Gouwy M; Lepers SA; Van Damme J; Struyf S
Angiogenesis; 2014 Jul; 17(3):631-40. PubMed ID: 24469069
[TBL] [Abstract][Full Text] [Related]
13. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
14. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
[TBL] [Abstract][Full Text] [Related]
15. Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
Struyf S; Salogni L; Burdick MD; Vandercappellen J; Gouwy M; Noppen S; Proost P; Opdenakker G; Parmentier M; Gerard C; Sozzani S; Strieter RM; Van Damme J
Blood; 2011 Jan; 117(2):480-8. PubMed ID: 20980681
[TBL] [Abstract][Full Text] [Related]
16. Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12.
Inngjerdingen M; Rolstad B; Ryan JC
J Immunol; 2003 Sep; 171(6):2889-95. PubMed ID: 12960311
[TBL] [Abstract][Full Text] [Related]
17. CXCR3/CXCL10 expression in the synovium of children with juvenile idiopathic arthritis.
Martini G; Zulian F; Calabrese F; Bortoli M; Facco M; Cabrelle A; Valente M; Zacchello F; Agostini C
Arthritis Res Ther; 2005; 7(2):R241-9. PubMed ID: 15743470
[TBL] [Abstract][Full Text] [Related]
18. Designing an improved T-cell mobilising CXCL10 mutant through enhanced GAG binding affinity.
Gerlza T; Nagele M; Gschwandtner M; Winkler S; Kungl A
Protein Eng Des Sel; 2019 Dec; 32(8):367-373. PubMed ID: 31974585
[TBL] [Abstract][Full Text] [Related]
19. Antibody Neutralization of CXCL10
Bonvin P; Gueneau F; Buatois V; Charreton-Galby M; Lasch S; Messmer M; Christen U; Luster AD; Johnson Z; Ferlin W; Kosco-Vilbois M; Proudfoot A; Fischer N
J Biol Chem; 2017 Mar; 292(10):4185-4197. PubMed ID: 28154179
[TBL] [Abstract][Full Text] [Related]
20. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E; Kremer V; Childs R; Lundqvist A
Cancer Immunol Immunother; 2015 Feb; 64(2):225-35. PubMed ID: 25344904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
